Patents by Inventor George Miljanich
George Miljanich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11834456Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: GrantFiled: January 26, 2022Date of Patent: December 5, 2023Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Publication number: 20220259218Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: ApplicationFiled: January 26, 2022Publication date: August 18, 2022Inventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Patent number: 11279706Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.Type: GrantFiled: March 29, 2018Date of Patent: March 22, 2022Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Patent number: 11236097Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: GrantFiled: March 29, 2018Date of Patent: February 1, 2022Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, George Miljanich, Anton Delwig, Jacob Beckley, Grant Masaaki Shibuya, Justin Du Bois
-
Publication number: 20200102318Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.Type: ApplicationFiled: March 29, 2018Publication date: April 2, 2020Inventors: John MULCAHY, Hassan PAJOUHESH, George MILJANICH, Anton DELWIG, Jacob BECKLEY, Grant Masaaki SHIBUYA, Justin DU BOIS
-
Publication number: 20200102317Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1, and X2 are as described herein.Type: ApplicationFiled: March 29, 2018Publication date: April 2, 2020Inventors: John MULCAHY, Hassan PAJOUHESH, George MILJANICH, Anton DELWIG, Jacob BECKLEY, Grant Masaaki SHIBUYA, Justin DU BOIS
-
Publication number: 20190374644Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.Type: ApplicationFiled: August 27, 2019Publication date: December 12, 2019Inventors: Julien MAMET, Scott HARRIS, George MILJANICH, Rick ORR, William K. SCHMIDT, Tony YAKSH, David C. YEOMANS
-
Patent number: 10434178Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.Type: GrantFiled: April 5, 2017Date of Patent: October 8, 2019Assignee: Adynxx Sub, Inc.Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
-
Patent number: 10112953Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1 and X3 are as described herein.Type: GrantFiled: September 30, 2016Date of Patent: October 30, 2018Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: John Mulcahy, Hassan Pajouhesh, Grant Masaaki Shibuya, Anton Delwig, George Miljanich, Justin Du Bois
-
Patent number: 10106549Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.Type: GrantFiled: April 9, 2015Date of Patent: October 23, 2018Assignees: SITEONE THERAPEUTICS, INC., THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Hassan Pajouhesh, George Miljanich, John Mulcahy, Justin Du Bois, Matthew Axtman, James Walker, Jeffrey E. Merit
-
Publication number: 20180015165Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.Type: ApplicationFiled: April 5, 2017Publication date: January 18, 2018Applicant: Adynxx, Inc.Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
-
Publication number: 20170233398Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R1, X1 and X3 are as described herein.Type: ApplicationFiled: September 30, 2016Publication date: August 17, 2017Inventors: John MULCAHY, Hassan PAJOUHESH, Grant Masaaki SHIBUYA, Anton DELWIG, George MILJANICH, Justin DU BOIS
-
Patent number: 9700624Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.Type: GrantFiled: May 9, 2013Date of Patent: July 11, 2017Assignee: Adynxx, Inc.Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K Schmidt, Tony Yaksh, David C Yeomans
-
Publication number: 20170029431Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function, for example conditions associated with pain. The compounds are 10?,11?-modified saxitoxins. The compounds are optionally additionally modified at carbon 13. In certain embodiments, the 10?,11?-modified saxitoxins are of Formula I: where R1, R2 and R3 are as described herein. Also provided herein are methods of treating pain in a mammal comprising administering an effective treatment amount of a 10?,11? modified saxitoxin or composition to a mammal. In an embodiment, the mammal is a human.Type: ApplicationFiled: April 9, 2015Publication date: February 2, 2017Inventors: Hassan PAJOUHESH, George MILJANICH, John MULCAHY, Justin DU BOIS, Matthew AXTMAN, James WALKER, Jeffrey E. MERIT
-
Publication number: 20150111956Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.Type: ApplicationFiled: May 9, 2013Publication date: April 23, 2015Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K Schmidt, Tony Yakash, David C Yeomans
-
Publication number: 20070269528Abstract: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: July 31, 2007Publication date: November 22, 2007Inventors: David Ellis, George Miljanich, David Shields
-
Publication number: 20070270353Abstract: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: July 31, 2007Publication date: November 22, 2007Inventors: DAVID ELLIS, George Miljanich, David Shields
-
Publication number: 20050192218Abstract: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: October 1, 2004Publication date: September 1, 2005Inventors: David Ellis, George Miljanich, David Shields